The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate

Journal of Bone and Mineral Research

Volumn 25, Issue 3, 2010, Pages 455-462

  Middleton, Edward T ^a   Steel, Susan A ^a   Aye, Mo ^a   Doherty, Sheelagh M ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bisphosphonates; Bone mineral density; Bone turnover markers; Osteoporosis; Strontium

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; BONE DENSITY CONSERVATION AGENT; ORGANOMETALLIC COMPOUND; THIOPHENE DERIVATIVE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTHRALGIA; ARTICLE; BLOATING; BONE DENSITY; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; DEFECATION HABIT; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG UPTAKE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEEL; HUMAN; LEG CRAMP; LETHARGY; MAJOR CLINICAL STUDY; NAUSEA; OSTEOPOROSIS; PRURITUS; SIDE EFFECT; SPINE; TREATMENT RESPONSE; UNITED KINGDOM; VERTEBRA FRACTURE; BONE; BONE REGENERATION; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; METABOLISM; MIDDLE AGED; OSTEOLYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; TIME;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REGENERATION; BONE RESORPTION; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES; TIME FACTORS;

EID: 77951049321     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090821     Document Type: Article

References (29)

1. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-468. (Pubitemid 38133766)
2. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816-2822. (Pubitemid 40686329)
3. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int. 2001;69:121-129. (Pubitemid 32912229)
4. Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008;23:215-222. (Pubitemid 351160035)
5. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res. 2004;19:2012-2020. (Pubitemid 41103416)
6. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. 2008 Available at: www.nice.org.uk/nicemedia/pdf/TA161quickrefguide.pdf. Accessed May 1, 2009.
7. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX) - a randomized trial. JAMA. 2006;296:2927-2938.
8. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199. (Pubitemid 38339363)
9. Boivin G, Farlay D, Simi C, Meunier PJ. Bone strontium distribution and degree of mineralisation of bone after 2 and 3 years of treatment with strontium ranelate in postmenopausal women. Calcif Tissue Int. 2006;78:S36.
10. Boivin G, Khebbab MT, Jaurand X, Farlay D, Meunier PJ, Delmas PD. Localization of strontium, by X-ray microanalysis cartography, in bone biopsies of postmenopausal osteoporotic women treated for 3 years with strontium ranelate. Calcif Tissue Int. 2007;80:S118.
11. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008;23:1591-1600. (Pubitemid 351398563)
12. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004;19:745-751. (Pubitemid 41094385)
13. Blake GM, Preston N, Patel R, Herd RJ, Fogelman I. Monitoring skeletal response to treatment which site to measure in the femur? J Clin Densitom. 2000;3:149-155.
14. Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporos Int. 2003;14:S56-65.
15. Blake GM, Lewiecki EM, Kendler DL, Fogelman I. A review of strontium ranelate and its effect on DXA scans. J Clin Densitom. 2007;10:113-119. (Pubitemid 46678864)
16. Noble BS, Reeve J. Osteocyte function, osteocyte death and bone fracture resistance. Mol Cell Endocrinol. 2000;159:7-13. (Pubitemid 30067635)
17. Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S12911) administration. J Bone Miner Res. 1996;11:1302-1311. (Pubitemid 26282531)
18. Liney GP, Bernard CP, Manton DJ, Turnbull LW, Langton CM. Age, gender, and skeletal variation in bone marrow composition: a preliminary study at 3.0 tesla. J Magn Reson Imaging. 2007;26:787-793.
19. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006;2:35-43.
20. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int. 2000;11:S66-76.
21. Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res. 2006;21:1113-1120. (Pubitemid 43962840)
22. Seibel MJ. Biochemical markers of bone turnover: I. Biochemistry and variability. Clin Biochem Rev. 2005;26:97-122.
23. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19:365-372. (Pubitemid 351199181)
24. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962-970. (Pubitemid 40712820)
25. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822. (Pubitemid 46698462)
26. Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008;42:129-138. (Pubitemid 350297175)
27. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone. 2001;29:176-179. (Pubitemid 32734498)
28. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone. 1996;18:517-523. (Pubitemid 26257871)
29. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93:852-860. (Pubitemid 351398563)